|
Description
| Athersys, Inc. (NASDAQ:ATHX and Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI (NASDAQ:TSX: ANP ANP>), have announced that Athersys has received authorization from the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial evaluating the safety of MultiStem(R) in the treatment of acute myocardial infarction (AMI). The companies believe that this represents the first clinical study of a scalable, allogeneic cell product injected directly into and around the zone of myocardial injury from an intra-coronary approach. This approach is designed to provide the clinician with a readily usable, "off-the-shelf" cell therapy that combines the benefits of efficient, localized delivery and enhanced cell retention in the area of greatest need.... |
More articles from Biotech Equipment Update
ARIZONA HEART INNOVATIVE SELLS ENDOVASCULAR DEVICE., February 01, 2008
Looking for additional articles?
Click here
to search our database of over 3 million articles.
|
